Ulcerative colitis trials in United States

In United States 112 Also abroad 381

112 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Where
Bethesda
Age
1 day to 75 years
People
1,000
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT00001184
No phaseTaking people
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Where
Chapel Hill, Charleston, Charlotte, Chevy Chase, Chicago, Cincinnati, Glen Burnie, Houston, Kissimmee, La Jolla, Littleton, Los Alamitos, Lutz, Marlton, Mesa, Morgantown, Naperville, New York, Orlando, San Antonio, Southlake, Tacoma, Westlake
Age
18 years to 64 years
People
300
Run by
Pfizer
See details and how to joinNCT06398626
Phase 2Taking people
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Where
Indianapolis, New York
Age
2 years to 11 years
People
24 worldwide
Run by
Pfizer
See details and how to joinNCT07470879 · EU 2025-523100-77-00
No phaseNot yet taking people in United States
Online Pain Education for Crohn's Disease and Ulcerative Colitis
Where
Los Angeles
Age
18 years and over
People
60
Run by
Cedars-Sinai Medical Center
See details and how to joinNCT07671313
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Cordova
Age
16 years to 80 years
People
350
Run by
Hoffmann-La Roche
See details and how to joinNCT07846683 · EU 2026-526684-37-00
No phaseTaking people
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
Where
Birmingham, Boston, Lake Forest, Lebanon, Los Angeles, Louisville, Miami, New York, Orlando, Pittsburgh, Rochester, Syracuse
Age
18 years to 85 years
People
126
Run by
Northwestern University
See details and how to joinNCT05987852
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Arcadia, Atlanta, Aurora, Baltimore, Baton Rouge, Baytown, Bellevue, Boston, Canoga Park, Canton, Chapel Hill, Charlotte, Chesterfield, Chicago, Clermont, Clive, Colorado Springs, Columbus, Coral Springs, Cordova, Coronado, Dallas, Dayton, Denver, Des Plaines, Durham, East Orange, Fargo, Fayetteville, Folsom, Freehold, Gainesville, Glenview, Greenbelt, Gurnee, Harlingen, Hershey, Houma, Idaho Falls, Jackson, Kansas City, Kingwood, Kissimmee, Lake Jackson, Lancaster, Las Vegas, Lexington, Liberty, Little Rock, Los Angeles, Lubbock, Lynchburg, Mandeville, Marrero, Maspeth, Mesquite, Metairie, Miami, Monroe, Morristown, Murrieta, New Albany, New Haven, New Iberia, New York, Norman, Orlando, Oxnard, Palmetto Bay, Peoria, Philadelphia, Pittsburgh, Portland, Providence, Raleigh, Richmond, Sacramento, San Antonio, San Diego, Sandy Springs, Santa Maria, Scottsdale, Snellville, Somers Point, Southlake, Sparta, Springboro, Suwanee, Tampa, Tarzana, The Bronx, Thousand Oaks, Toledo, Tomball, Tucson, Tyler, Valencia, Vancouver, Victorville, Waterloo, West Columbia, West Jordan, Westlake, Worcester, Wyoming
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184996
Phase 2Taking people
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Where
Anaheim, Colorado Springs, Coronado, Englewood, Inverness, Kansas City, Liberty, Macon, Miami, New Orleans, Orlando
Age
18 years to 75 years
People
100 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07463183 · EU 2025-523479-49-00
Phase 2Taking people
Confirmatory Clinical Study in Active Ulcerative Colitis
Where
Fayetteville, High Point, Miami, Orlando, Palmetto Bay, San Antonio
Age
16 years and over
People
204 worldwide
Run by
MRM Health NV
See details and how to joinNCT07296315 · EU 2025-524682-24-00
Phase 2Taking people
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Albany, Baton Rouge, Bellevue, Bristol, Brunswick, Clifton, Cordova, Dayton, Des Plaines, Garland, Georgetown, Glenview, Gurnee, Houston, Lubbock, Mandeville, Mansfield, Milwaukee, Orlando, Providence, Richmond, Rochester, San Diego, Southlake, St Louis, Sun City, Tacoma, Tupelo, Tyler, Westlake
Age
18 years to 75 years
People
204 worldwide
Run by
Palisade Bio
See details and how to joinNCT07845487
Phase 1Taking people
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Crohn's Disease or Ulcerative Colitis
Where
Naples
People
15 worldwide
Run by
The Foundation for Orthopaedics and Regenerative Medicine
See details and how to joinNCT05003947
Phase 2/3Taking people
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Where
Atlanta, Boston, Chapel Hill, Charleston, Charlotte, Cleveland, Detroit, Fort Worth, Garden Grove, Hartford, Hershey, Houston, Indianapolis, Iowa City, Loma Linda, Los Angeles, Milwaukee, New York, Oklahoma City, Orlando, Palo Alto, Park Ridge, Phoenix, Portland, Rochester, Sacramento, Seattle, Springfield, St Louis, Tacoma, Tucson, Washington D.C., Worcester
Age
2 years to 17 years
People
120 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT05076175
No phaseTaking people
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
Where
Chicago
Age
18 years to 75 years
People
200
Run by
University of Chicago
See details and how to joinNCT06693310
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Atlanta, Baton Rouge, Chesterfield, Colorado Springs, Columbus, Coronado, Fayetteville, Gurnee, Idaho Falls, Kingwood, Kissimmee, Lexington, Liberty, Lubbock, Mandeville, Maspeth, Miami, Monroe, Murrieta, New Albany, New York, Pittsburgh, Providence, San Antonio, Southlake, Sparta, Tampa, Tucson, Tyler, Vancouver, Victorville, Westlake, Worcester, Wyoming
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07185009
Phase 1Taking people
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Where
Chula Vista, Miami
Age
18 years to 60 years
People
25 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07665723 · EU 2025-524060-38-00
Phase 3Taking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Charleston, Cleveland, Detroit, Hershey, Loma Linda, Morristown, New York, Oklahoma City, Orange, Park Ridge, Phoenix, Tacoma
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
No phaseTaking people
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
Where
Chapel Hill, Chevy Chase, Cincinnati, Nashville, New Orleans, New York
Age
18 years and over
People
200
Run by
Mercy Medical Center
See details and how to joinNCT06750731
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Atlanta, Boston, Fairfax, Fort Worth, Hartford, New York, Philadelphia, San Francisco, St Louis, Waltham
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
No phaseTaking people
Family Members at INcreased-risk for Developing Inflammatory Bowel Disease
Where
Boston
Age
14 years and over
People
50
Run by
Massachusetts General Hospital
See details and how to joinNCT06655415
Phase 1Taking people
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Where
Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
Age
18 years and over
People
300 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03816345
No phaseTaking people
Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis
Where
Charlottesville
Age
18 years to 64 years
People
160
Run by
Fuller Research Foundation
See details and how to joinNCT07524244
Phase 4Not yet taking people in United States
Combination CurQD and Vedolizumab in Ulcerative Colitis
Where
New York
Age
18 years to 80 years
People
160 worldwide
Run by
Ryan C Ungaro
See details and how to joinNCT07665294
No phaseNot yet taking people in United States
The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares
Where
Winston-Salem
Age
21 years and over
People
42
Run by
Wake Forest University Health Sciences
See details and how to joinNCT07143188
Phase 4Not yet taking people in United States
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Where
San Francisco
Age
18 years to 75 years
People
50
Run by
University of California, San Francisco
See details and how to joinNCT07502339
Phase 2Taking people
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Where
Cleveland, Miami, Roswell, Tampa
Age
18 years to 75 years
People
120 worldwide
Run by
Athos Therapeutics Inc
See details and how to joinNCT07513181 · EU 2024-520183-33-00